Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phenylephrine
Drug ID BADD_D01762
Description Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.[A187370] The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s.[A187376] Phenylephrine was granted FDA approval in 1939.[L9413]
Indications and Usage Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
Marketing Status Prescription
ATC Code C01CA06; R01AA04; R01AB01; R01BA03; S01FB01; S01GA05
DrugBank ID DB00388
KEGG ID D08365
MeSH ID D010656
PubChem ID 6041
TTD Drug ID D0O6IU
NDC Product Code 42961-205; 0498-3331; 57218-710; 0498-3330
Synonyms Phenylephrine | (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol | Metasympatol | Mezaton | Phenylephrine Hydrochloride | Phenylephrine Tannate | Tannate, Phenylephrine | Metaoxedrin | Neo-Synephrine | Neo Synephrine | Neosynephrine
Chemical Information
Molecular Formula C9H13NO2
CAS Registry Number 59-42-7
SMILES CNCC(C1=CC(=CC=C1)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hemiparesis17.01.04.0010.006074%
Hyperaemia24.03.02.002--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.012148%
Hypersensitivity10.01.03.0030.006074%
Hypertension24.08.02.0010.060738%
Hypertensive crisis24.08.01.001--Not Available
Hypotension24.06.03.0020.021258%
Immune system disorder10.02.01.001--Not Available
Keratitis06.04.02.002--
Lacrimation increased06.08.02.004--
Lactic acidosis14.01.01.0020.006074%Not Available
Loss of consciousness17.02.04.004--Not Available
Miosis17.02.11.002; 06.05.03.003--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial ischaemia24.04.04.010; 02.02.02.0080.001584%Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Nodal rhythm02.03.02.0060.006074%Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Pain in jaw15.02.01.0030.006074%Not Available
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.024295%Not Available
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Photophobia17.17.02.006; 06.01.01.0040.009111%
Piloerection23.02.06.005--Not Available
Pruritus23.03.12.001--
Pulmonary oedema22.01.03.003; 02.05.02.0030.009111%
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages